Thubrikar Aortic Valve

Thubrikar Aortic Valve is a privately-held, US-based innovator targeting the transcatheter aortic valve replacement (TAVR) market with a focus on long-term durability, a key unmet need. The company's lead product, the Optimum TAVI System, is currently in clinical trials in Europe (for CE Mark) and has demonstrated promising early clinical results in a 12-patient study, with one First-in-Human patient exceeding 6 years of follow-up. The company has a strategic manufacturing and commercialization partnership with Labcor Laboratórios for South America and is positioning its valve as a potential new standard of care for a broader patient population, including younger patients.

A transcatheter aortic valve implantation (TAVI) system engineered from first principles based on over 30 years of research into the natural aortic valve's geometry, mechanics, and dynamics. The platform focuses on optimizing leaflet design and stress distribution to maximize long-term durability and hemodynamic performance.

The TAVR market is dominated by large, established players like Edwards Lifesciences, Medtronic, and Boston Scientific. Thubrikar's competition is differentiated by its singular focus on durability from first-principles design, rather than incremental improvements to existing valve architectures. It competes by aiming to solve a fundamental limitation of current technologies.